Home » Illumina

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Jan 10, 2019

Consumer Genomics Poised for Growth in 2019 as Providers Diversify Offerings

Premium

With ever more data in hand, providers are seeking to enhance their services, providing more detailed ancestry estimates while introducing new offerings around genetic traits and health.

Jan 08, 2019

Illumina to Launch New NovaSeq Chip, iSeq Kit; Grow Oncology and Reproductive Health Business

The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.

Jan 04, 2019

Illumina, PierianDx to Collaborate on Cancer Sequencing Assays

The companies will integrate PierianDx's informatics solution with two of Illumina's NGS cancer research panels and as well as future IVD products.

Jan 03, 2019

CareDx, Pacific Biosciences Drive GenomeWeb Index's Outperformance of Broader Market in 2018

The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.

Dec 27, 2018

US District Court Sides With Roche, Ariosa in NIPT Patent Case Filed by Illumina

The court cited previous US Supreme Court rulings, including Mayo vs. Prometheus, in determining that certain claims of Illumina's patents were invalid.

Dec 21, 2018

Pediatric Genetic Disease Contributes Disproportionately to Healthcare Costs

The analysis found that charges for suspected genetic diseases account for between 11 percent and 46 percent of pediatric healthcare costs in the US.

Dec 21, 2018

Estonia to Invest €2.3M to Genotype 50K More People in 2019

The government has also pledged €5 million from the European Regional Development Fund to support the integration of genetic data into routine medical care.

Dec 19, 2018

French Medical Genomics Initiative's Pilot Sequencing Platforms Set to Commence Operations

Premium

The launch of the sequencing platforms is a milestone for the Plan France Médecine Génomique 2025, a €670 million initiative the French government announced two years ago.

Dec 18, 2018

M&A Deals in MDx/Omics Research Tools Space Up 12 Percent in 2018

There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.

Dec 07, 2018

Amended Lawsuit Against Illumina, Thermo Fisher, Others Names Additional Defendants

The suit names additional defendants and includes additional details about the technology Illumina is accused of appropriating.

Pages

The Scan

More Common Than Thought

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

Even for Prizes, Women Get Less Money

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

This Week in Nature

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Scramble to Keep the Work Alive

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.